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Objective: Aim of this study is to investigate the effects of Glucosamine (GlcN) and its peptidyl-
derivative, 2-(N-Acetyl)-L-phenylalanylamido-2-deoxy-b-D-glucose (NAPA), on extracellular matrix
(ECM) synthesis in human primary chondrocytes (HPCs).
Methods: Dose-dependent effect of GlcN and NAPA on Glycosaminoglycan (GAG), Collagen type II (Col2)
and Small Leucine-Rich Proteoglycans (SLRPs) was examined by incubating HPCs, cultured in micro-
masses (3D), with various amounts of two molecules, administered as either GlcN alone or NAPA alone or
GlcN plus NAPA (G þ N). Immunohystochemical and immunoﬂuorescent staining and biochemical
analysis were used to determine the impact of the two molecules on ECM production. Gene expression
analysis was performed by TaqMan Real-Time Polymerase Chain Reaction (PCR) assays.
Results: The lowest concentration to which GlcN and NAPA were able to affect ECM synthesis was 1 mM.
Both molecules administered alone and as G þ N stimulated GAGs and SLRPs synthesis at different
extent, NAPA and mainly G þ N stimulated Col2 production, whereas GlcN was not effective. Both
molecules were able to induce Insulin Growth Factor-I (IGF-I) and to stimulate SOX-9, whereas NAPA and
G þ N were able to up-regulate both Hyaluronic Acid Synthase-2 and Hyaluronic acid. Very interesting is
the synergistic effect observed when chondrocyte micromasses were treated with G þ N.
Conclusions: The observed anabolic effects and optimal concentrations of GlcN and NAPA, in addition to
beneﬁcial effects on other cellular pathways, previously reported, such as the inhibition of IKKa, could be
useful to formulate new cartilage repair strategies.
© 2014 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA), characterized by enhanced degradation of
extracellular matrix (ECM) molecules1 is mainly treated with Non-
Steroidal Anti-Inﬂammatory Drugs (NSAIDs), in order to reduceA. Scotto d'Abusco, Depart-
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cotto d'Abusco).
ternational. Published by Elsevier Larthritis-related symptoms. In the last decades an increasing
number of patients have started to use supplements, such as
Glucosamine (GlcN). The rationale for using this molecule is that
GlcN is an amino sugar, which constitute the glycosaminoglycans
(GAGs) present in the cartilage and for this reason is considered a
potential chondroprotective agent.
Several in vivo clinical trials, based on oral GlcN admin-
istration2e4, as well as experiments performed in vitro by stimu-
lating both animal and human chondrocytes with GlcN5e7, have
been performed reporting inconsistent outcomes. Recent review8
analyzed all the in vivo and in vitro evidences for the mechanism
of action of GlcN, highlighting that this molecule has many
potential mechanisms of action on articular structures and
concluding that the inconsistent outcomes, found in differenttd. All rights reserved.
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trials and publication bias. Different GlcN formulations, such as
GlcN hydrochloride and GlcN sulfate, have been used in various
systems, GlcN sulfate is recommended in the major guidelines,
while GlcN hydrochloride cannot be recommended due to few
available clinical data. However, at this time there are no clear in-
dications that the two formulations could be distinguished from
each other in terms of biological activity8.
We have previously analyzed the anabolic effects of GlcN and its
N-acetyl phenylalanine derivative (NAPA)9 in a rabbit OA model,
ﬁnding very encouraging results10. In our model, intra-articular
administration of GlcN and NAPA was very effective in reducing
cartilage changes induced in rabbit knee by intra-articular injection
of vitamin A. GlcN and NAPA intra-articular administration allows
higher concentrations to be reached in the joints compared to oral
administration, thus providing an explanation for the ability of both
molecules to interfere with OA progression.
However, other in vivo studies on animal experimental OA
showed that oral and intramuscular administration of GlcN pro-
duced chondroprotective and anti-inﬂammatory effects11e14.
Previously, we also studied the effects of GlcN and NAPA on
inﬂammatory pathways, ﬁnding that both molecules can interfere
with MAP kinase and NF-kB pathways15,16, in particular by inter-
fering with IKKa activity.
Aim of this paper is to analyze the effectiveness of GlcN and
NAPA on the biosynthetic activity and hence the matrix production
of human primary chondrocytes (HPCs). In order to study chon-
drocytes in physiological culture conditions, we cultured cells in
micromasses, which represent a good tridimensional culture
model17 and explored the ability of GlcN and NAPA to stimulate the
synthesis of ECM components, such as GAG, collagen type II (Col2),
Aggrecan (ACAN) and Small Leucine-Rich Proteoglycans (SLRPs).
Furthermore, since the synthesis of these ECM components is
under the control of factors such as Transforming Growth Factor
(TGF)-b, Insulin Growth Factor (IGF)-I and Osteogenic Protein (OP)-
118,19, we evaluated the ability of GlcN and NAPA to affect IGF-I
expression level, providing an explanation for the anabolic activ-
ity of the two molecules.
Materials and methods
Isolation of HPCs
HPCs were isolated from femoral and tibial condyles and from
femoral heads, obtained from patients who underwent a total knee
and hip arthroplasty. Full ethical consent was obtained from all
donors and the Research Ethics Committee, Sapienza University of
Roma, approved the study.
Articular cartilages were aseptically dissected from 15 patients
with an age range of 59e70 years and OA grades IeII (normal or
only mild ﬁbrillations according to the modiﬁed Outerbridge
scale)20, selecting areas of macroscopically normal cartilage. Ex-
periments were performed with chondrocytes isolated as previ-
ously described in Ref. 15 and cultured in micromasses, prepared as
previously described in Ref. 17, using chondrocytes at ﬁrst passage
(p1) from each analyzed patient and repeated with samples from
three different donors.
Cell treatment
Cells were left untreated (CTL) or treated for the required time,
with 1, 2.5 or 5 mM GlcN-HCl (SigmaeAldrich, St. Louis, MO, USA)
or with 2-(N-Acetyl)-L-phenylalanylamido-2-deoxy-b-D-glucose
(NAPA), synthesized in our laboratory9 or with both molecules
GlcN þ NAPA (G þ N).Immunohystochemistry and immunoﬂuorescence
Micromasses were cultured for 2, 3 and 4-weeks then ﬁxed with
4% paraformaldehyde and parafﬁn embedded. Sequentially sec-
tions were used for HematoxylineEosin (HE), Alcian Blue (AB) and
Periodic-acid Schiff (PAS) staining. Other sections were used for
immunohystochemical and immunoﬂuorescence analyses using
mouse monoclonal antibody anti-Col2 (10 mg/mL, ab3092, Abcam,
Cambridge, UK) and anti-SOX-9 (10 mg/mL, AB5809, Millipore,
Temecula, CA, USA).
Quantitative GAG assay
GAG production by chondrocyte micromasses was quantiﬁed,
both in cell lysate and in the culture medium, by
1,9-dimethylmethylene blue (DMMB) method essentially as
described by Farndale et al.21. Shark chondroitin sulfate C
(SigmaeAldrich) was used as standard. DNA content was deter-
mined using Hoechst 33,258 dye22.
Transmission Electron Microscopy (TEM)
Condrocyte micromasses untreated (CTL) or treated with GlcN,
NAPA, and GþN for 2 and 3weekswere processed for conventional
TEM and examined at 100 kV with a Philips EM208 S electron
microscope.
RNA extraction and reverse-transcription
Total RNA was extracted with TRIZOL (Invitrogen, Carlsbad, CA,
USA), puriﬁed using micro RNeasy column (Qiagen, Valencia, CA,
USA) and reverse transcribed by Improm II enzyme, (Promega
Corporation, Madison, WI, USA).
Quantitative-Real Time-PCR (Q-RT-PCR)
Q-RT-PCR analysis was performed using an ABI Prism 7300
(AppliedBiosystems, FosterCity, CA,USA).Ampliﬁcationwas carried
out using Taqman Universal PCR Master Mix (Applied Biosystems).
Taqman primer sets were purchased as predesigned oligonucleo-
tides (GAPDH Hs02758991_g1, Col1a1 Hs00164004_m1, Col2a1
Hs00264051_m1, Col3a1 Hs00943809_m1, ACAN Hs00153936_m1,
BGN Hs00959141, LUM Hs00929860_m1, _m1, DCN
Hs00754870_m1, CD44 Hs01075861_m1, SOX-9 Hs01001343_g1,
HAS-2 Hs00193435_m1, IGF-I Hs01547656) (Applied Biosystems).
Relative expression levels were normalized with glycer-
aldheyde-3-phosphate dehydrogenase (GAPDH) as housekeeping
gene. Data were analyzed both by 2DDCt method23 and expressed
as fold change compared to CTL and by DCt method24. Col1a1,
Col2a1, Col3a1 and ACAN mRNA transcript abundance relative to
GAPDH were determined by 2DCt method23.
Flow cytometry
The chondrocytes were harvested from micromasses and the
presence of CD44þ cells were determined by using CD44-APC
antibody (1 mg/mL, MAB-92000APC, Immunological Sciences,
Roma, Italy) and analyzed by BD Accuri C6 ﬂow cytometer (BD
Bioscience, Milano, Italy).
ELISA
Concentration of HA was measured, both in cell lysate and in
culture medium, using Hyaluronan Enzyme-Linked Immunosor-
bent assay Kit (HA-ELISA, MyBiosurces, San Diego, CA, USA).
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IGF-I ELISA kits (RayBiotech, Inc., Norcross, GA, USA).
Statistics
All data were obtained from at least three independent experi-
ments (conducted with samples from three different donors), each
performed either in duplicate or in triplicate. All data were statis-
tically analyzed by using the Graph Prism software. For each set of
data the normality test and the Bartlett's test were used to verify
Gaussian distribution and homoschedasticity, respectively. Data
were then analyzed by two-way ANalysis Of VAriance (ANOVA) or
one-way ANOVA, according to the experimental design. ANOVA for
repeated measures was used when appropriate. To perform
multiple comparisons, Dunnet's test (in most cases) or Tukey's
test were used as post hoc after one-way ANOVA, while Bonferro-
ni's test was used as post hoc after two way ANOVA. The signiﬁcant
results from the statistical analyses conducted are reported in
Table I and/or in the ﬁgure legends. All not statistically signiﬁcant
results are not shown.
Results
Effect of GlcN and NAPA on ECM synthesis
To measure the ability of NAPA and GlcN to stimulate ECM
production, HPCs were cultured in micromasses and left untreated,
CTL, or exposed to 1, 2.5 and 5 mM of GlcN, NAPA and GlcN þ NAPA
(G þ N) for 2 weeks. At the end of exposure time, chondrocyte
micromasses were analyzed by DMMB assay to measure GAG
production and by Real time PCR to analyze Col2 and ACAN mRNA
expression level. Results are reported in Supplementary Figs. 1 and
2. The lowest concentration able to stimulate the progression of
ECM synthesis was 1 mM for both GlcN and NAPA. Therefore, for
further analysis, micromasses were treated with 1 mM GlcN, 1 mM
NAPA and 0.5 mM GlcN þ 0.5 mM NAPA, in order to obtain 1 mM
ﬁnal concentration, for 2 weeks and stained by HE, AB and PAS.
In the samples stained with HE, cells cultured in the presence of
GlcN and mainly in the presence of NAPA or G þ N appear disposed
around extracellular deposits, that are almost absent in CTL
[Fig.1(A)]. AB staining revealed that extracellular deposits contained
elevated GAG amount in NAPA- and G þ N- treated micromasses as
compared with GlcN-treated micromasses and to CTL, with the
highest GAG levels accumulating in G þ N-treated sample (i.e.,
G þ N > NAPA > GlcN > CTL) [Fig. 1(B)]. These ﬁndings were
conﬁrmed by PAS staining, where extracellular deposits resulted
stained inpurple, indicative ofGAG/proteoglycan contents [Fig.1(C)].
Analysis of slices obtained by micromasses cultured for 3 or 4
weeks showed that cells in CTL begin to produce ECM deposition,Table I
Results of the two-way ANOVA for repeated measures (with treatment as the within
factor and time as the between factor) of mRNA levels of selected genes observed in
the samples treated with GlcN, NAPA and G þ N for 1, 4, 7 and 10 days
Ftreatment (df: 3/24) Ftime (df: 3/24) Finteraction (df: 9/24)
Col1 2.67 (P ¼ 0.0703) 0.71 (P ¼ 0.5726) 1.02 (P ¼ 0.4520)
Col2 49.62 (P < 0.0001) 70.59 (P < 0.0001) 53.68 (P < 0.0001)
Col3 0.84 (P ¼ 0.4839) 0.94 (P ¼ 0.4635) 0.59 (P ¼ 0.7955)
ACAN 1.56 (P ¼ 0.2242) 1.41 (P ¼ 0.3096) 1.15 (P ¼ 0.3662)
BGN 132.42 (P < 0.0001) 109.58 (P < 0.0001) 77.59 (P < 0.0001)
LUM 39.93 (P < 0.0001) 19.98 (P ¼ 0.0004) 10.08 (P < 0.0001)
DCN 3.52 (P ¼ 0.0304) 4.59 (P ¼ 0.0377) 4.73 (P ¼ 0.0011)
CD44 14.03 (P < 0.0001) 15.87 (P ¼ 0.0010) 10.56 (P < 0.0001)
SOX-9 47.72 (P < 0.0001) 51.97 (P < 0.0001) 39.04 (P < 0.0001)
HAS-2 29.96 (P < 0.0001) 24.19 (P ¼ 0.0002) 46.46 (P < 0.0001)
IGF-I 75.47 (P < 0.0001) 186.48 (P < 0.0001) 64.81 (P < 0.0001)but the number and size of these extracellular deposits were still
smaller than those found in samples treated with both molecules
(data not shown).
The production of GAG by micromasses cultured for 2 weeks,
was quantitatively measured by DMMB method, both in cell lysate
and in culture medium, conﬁrming a statistically signiﬁcant in-
crease of GAG accumulation in GlcN, NAPA and G þ N samples
[Fig. 1(D)]. Equal amount of DNA was found in each micromass
[Fig. 1(E)].
Col2 production was next explored by immunohystochemistry
and by immunoﬂuorescence in micromasses treated for 2 weeks.
Col2 synthesis was enhanced by NAPA and mainly by G þ N, the
latter in immunohistochemistry showed a very strong brown-
staining, whereas GlcN stimulated a very low production of Col2
[Fig. 2(A)]. This result was highlighted by immunoﬂuorescence
where the green ﬂuorescence associated to Col2 is highly appre-
ciable in sample treated with G þ N [Fig. 2(B)].
The ability of GlcN and NAPA to induce collagen synthesis was
also tested by TEM, in micromasses cultured for 2 weeks, where
chondrocytes showed large nuclei, more prominent in samples
treated with GlcN, NAPA and G þ N, and the cells were embedded
within ECM deposits. NAPA treated cells showed an abundant
production of collagen ﬁbrils and compact and dark ECM, whereas
GlcN displayed few and less organized collagen ﬁbrils within a
grainy and loose material [Fig. 2(C) and (D)]. In G þ N treated
sample we remarked a high matrix deposition [Fig. 2(C)] in which
we detected some cross-banded collagen ﬁbrils [Fig. 2(D), red ar-
row]. In CTL samples we found less organized collagen ﬁbrils and
low matrix deposition [Fig. 2(C) and (D)].
Ultrastructural analysis after 3-weeks treatment showed chon-
drocyte micromasses with increased ECM accumulation, a greater
organization [Fig. 3(A)] and collagen synthesis, several cross-
banded and randomly oriented collagen ﬁbrils were observed in
G þ N-treated cells [Fig. 3(B)].
Effect of GlcN and NAPA on mRNA gene expression
In order to explore if NAPA and GlcN were able to stimulate
mRNA expression of genes coding for cartilage speciﬁc markers, we
analyzed mRNA levels in chondrocyte micromasses cultured in the
presence of GlcN or NAPA or G þ N for 2 weeks, but we did not ﬁnd
gene modulation. Since changes in the mRNA expression levels can
be appreciated earlier compared to protein production modulation,
we analyzed mRNAmodulation after 1, 4, 7 and 10 days exposure to
our molecules (Fig. 4). These sets of datawere analyzed by two-way
ANOVA with time and treatment as the two factors. The results
from these analyses are reported in Table I, while the results from
the post hoc tests are reported in the legend of Fig. 4.
A statistically signiﬁcant up-regulation of Col2a1mRNA synthesis
by NAPA and by G þ N compared to CTL was found after 4 day
treatment, butnot after 7 and10days exposure.Wealso foundanup-
regulation inmRNA synthesis of three small proteoglycans, Byglican
(BGN), Lumican (LUM) and Decorin (DCN). BGN and LUM were up-
regulated by NAPA and G þ N at 4 days, by GlcN, NAPA and G þ N
after 7 day treatment and by GlcN after 10 day treatment. DCN was
up-regulatedbyNAPAafter 7 days andbyGlcNandGþNafter 10day
treatment. ACAN was never stimulated at any analyzed time; CD44
mRNA resulted up-regulated by GlcN, NAPA and G þ N after 4 day
treatmentandbyNAPAandGþNafter7day treatment. Toverify that
chondrocyte micromasses were not differentiating toward ﬁbro-
chondrocytes, we analyzed Col1a1 and Col3a1mRNA level thatwere
never stimulated at any analyzed time. We next analyzed the ability
of our molecules to stimulate mRNA expression of transcription
factors involved in chondrogenic progression and in ECM synthesis,
such as SOX-9 and Hyaluronic Acid Synthase-2 (HAS-2). We found
Fig. 1. Effect of GlcN and NAPA on GAG deposition. A, Chondrocyte micromasses untreated (CTL) or treated with 1 mM GlcN or with 1 mM NAPA or with 0.5 mM GlcN plus 0.5 mM
NAPA (G þ N) were stained with HE (original magniﬁcation 20). B, GAG/proteoglycan content was revealed by AB staining (original magniﬁcation 20). C, GAG/proteoglycan
content was revealed by PAS (original magniﬁcation 20). D, Quantitative measurement of sulfated GAG accumulation, revealed by DMMB assay. Data are reported as scatter plot
and mean value (horizontal bars) of GAG levels (micrograms) found in the medium (empty symbols) and in the cell lysate (ﬁlled symbols) of each of the three micromasses obtained
by the three donors. Each point of the scatter plot represents the average of duplicate observations made in the same sample. Two way ANOVA for repeated measures with
treatment as the between factor and type of sample (medium or cell lysate) as the within factor gave the following results: Ftreatment: 201.63, df: 3/8, P < 0.0001; Fsample: 876.96, df:
1/8, P < 0.0001; Finteraction: 0.24, df: 3/8, P ¼ 0.8636. *P < 0.05, **P < 0.01 and ***P < 0.001 vs the respective type of sample of the CTL group (Bonferroni's post hoc test for multiple
comparisons). E, Quantitative measurement of DNA levels extracted in each micromasses and reported as scatter plot and mean value (horizontal bars) of averages levels obtained
from duplicate observations made in the same sample.
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GþNafter4day treatmentandbyGþNafter7day treatment.HAS-2
mRNA level was increased by NAPA after 4 day treatment and by
G þ N after 7 days. The synthesis of ECM components is under the
control of some growth factors, such as IGF-I and OP-1, we analyzed
the ability of our molecules to stimulate the mRNA expression of
these growth factors ﬁnding that after 7 day treatment GlcN, NAPA
andGþNstimulated IGF-ImRNA level.OP-1wasnever stimulated in
any analyzed time (data not shown). The Real Time PCR data were
analyzed also by average of delta Ct (Table II), this analysis high-
lighted that ACAN as well as DCNmRNA level is mainly increased by
our culture conditions, whereas Col2 and BGN is increased by
molecule addition. Also LUM, CD44, SOX-9, IGF-I and HAS-2 mRNA
level were increased by molecule addition.
Determination of copy number relative to housekeeping gene
We analyzed the ECM protein mRNA copy numbers relative to
the housekeeping gene, using 2DCt method23. This type ofcalculation offers the possibility of comparing the relative abun-
dance of the transcripts and also to appreciate time variation (0, 4, 7
and 10 days) in the control conditions.
We observed a trend toward an increase of Col2 copy number in
micromasses cultured for 7 and 10 days, as compared with 0 and 4
day culture, although it did not reach statistical signiﬁcance.
Conversely, ACAN copy number remained quite stable at all
analyzed time andwas very high compared with Col2 copy number
(Fig. 5). Noteworthy, one sample, analyzed in triplicate, at day 7,
showed a very high amount of ACAN and Col2 mRNA level
compared with the other samples, probably due to the individual
variability. Col1 and Col3 copy numbers were quite stable and quite
low (Fig. 5).
Effect of GlcN and NAPA on CD44, SOX-9, IGF-I and HA production
To conﬁrm that the up-regulation of mRNA expression level
corresponded to up-regulation of protein level, we analyzed the
ability of our molecules to stimulate the production of CD44, SOX-9,
Fig. 2. Effect of GlcN and NAPA on Col2 synthesis. A, Results of immunohystochemical analysis of Col2 in parafﬁn-embedded micromasses untreated (CTL) or treated with 1 mM
GlcN or with 1 mM NAPA or with 0.5 mM GlcN plus 0.5 mM NAPA (G þ N), for 2 weeks, from one representative sample (original magniﬁcation 20). B, Results of immuno-
ﬂuorescence analysis of Col2 in parafﬁn-embedded micromasses (original magniﬁcation 20). C, TEM analysis of chondrocyte micromasses, revealing deposit of ECM (yellow
asterisk) (bar ¼ 2 mm). D, TEM analysis of the areas marked by yellow asterisk in panel C (bar ¼ 500 nm), cross-banded collagen ﬁbrils are indicated by red arrow. In this ﬁgure are
reported representative images of four different experiments.
Fig. 3. Effect of GlcN and NAPA on ECM synthesis after 3 weeks treatment. A, TEM analysis of chondrocyte micromasses untreated (CTL) or treated with 1 mM GlcN or with 1 mM
NAPA or with 0.5 mM GlcN plus 0.5 mM NAPA (G þ N), for 3 weeks, from one representative sample. ECM deposits are marked by yellow asterisk (bar ¼ 2 mm). B, TEM analysis of the
areas marked by yellow asterisk in panel C (bar ¼ 500 nm), cross-banded and randomly oriented collagen ﬁbrils can be observed. In this ﬁgure are reported representative images of
four different experiments.
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Fig. 4. Effect of GlcN and NAPA on mRNA expression level of ECM components, transcription factors and growth factors. Chondrocytes micromasses were left untreated (CTL) or
exposed at 1 mM GlcN or at 1 mM NAPA or at 0.5 mM GlcN plus 0.5 mM NAPA (G þ N) for 1, 4, 7 or 10 days. Panel shows the results of the Q-RT-PCR used to quantify the mRNA
levels of the following genes: Collagen1a1 (Col1), Collagen2a1 (Col2), Collagen3a1 (Col3), Aggrecan (ACAN), Byglican (BGN), Lumican (LUM), Decorin (DCN), CD44, SOX-9, HAS-2 and
IGF-I. Data are expressed as relative mRNA level with respect to GAPDH mRNA (2DDCt method) and are reported as mean and 95% conﬁdence interval of samples analyzed in
triplicate from each of the three micromasses obtained from the three donors. The results of the two way ANOVA of data sets for each gene are reported in Table I aaP < 0.01 and
aaaP < 0.0001 of GlcN-group vs CTL; bP < 0.05, bbP < 0.01, and bbbP < 0.001 of NAPA group vs CTL; cP < 0.05, ccP < 0.01, and cccP < 0.001 of G þ N group vs CTL (Bonferroni's post hoc
test for multiple comparisons).
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cytometry after 7 and 10 day treatment. After 7 days, GlcN, NAPA
and mainly G þ N treated cells showed higher number of CD44þ
cells compared with CTL [Fig. 6(A)], after 10 days, G þ N-treated
cells were still more positive to CD44 compared with GlcN, NAPA
and CTL (data not shown). The up-regulation of SOX-9 mRNA level,
after 7 day treatment, corresponded in GlcN-treated cells to an up-
regulation of protein into the cytosol, while in NAPA treated cells to
an increase in the space around the nucleus and in G þ N-treated
cells to the migration into the nucleus [Fig. 6(B)].HA levels found in the medium of micromasses treated for 7
days with NAPA or G þ N resulted signiﬁcantly up-regulated,
whereas it remained comparable to CTL in all other
samples [Fig. 6(C)]. IGF-I protein levels, after 7 days, were signiﬁ-
cantly up-regulated by all treatments [Fig. 6(D)].
Discussion
The aim of the present studywas to investigate the effect of GlcN
and in particular of its derivative, NAPA, synthesized in our
Table II
Data are reported as average of delta Ct [Ct(GOI)-Ct(GAPDH)]. Standard deviation is reported in parentheses
Treatments 1 day 4 days 7 days 10 days 1 day 4 days 7 days 10 days
Col1 Col2
CTL 7.95 (0.73) 9.76 (2.78) 8.77 (3.04) 8.91 (1.13) 9.92 (1.71) 8.43 (0.89) 6.20 (3.68) 6.06 (2.98)
GlcN 8.03 (0.69) 9,37 (2.73) 8.63 (.87) 9.31 (0.68) 9.70 (1.44) 8.07 (1.09) 6.31 (3.90) 5.67 (2.95)
NAPA 7.86 (0.69) 9.57 (3.63) 8.25 (3.05) 8.99 (1.28) 9.63 (1.43) 6.12 (0.92)*** 6.27 (3.56) 6.44 (2.82)
G þ N 7.87 (0.63) 10.18 (3.15) 9.93 (4.20) 9.35 (0.74) 9.56 (1.44) 6.89 (0.84)*** 6.36 (3.64) 5.52 (3.10)*
Col3 ACAN
CTL 7.71 (0.53) 8.68 (3.74) 9.56 (2.71) 8.79 (1.94) 5.08(1.30) 3.49 (1.50) 2.66 (1.43) 3.48 (1.93)
GlcN 7.85 (0.56) 8.37 (3.91) 9.13 (2.61) 9.31 (1.52) 5.13 (1.19) 3.58 (1.28) 2.72 (1.66) 3.18 (1.88)
NAPA 7.80 (0.42) 8.47 (4.39) 9.26 (2.80) 8.83 (1.86) 4.90 (1.18) 3.37 (1.42) 2.67 (1.44) 3.20 (2.41)
G þ N 7.75 (0.44) 8.50 (4.29) 10.20 (4.28) 8.81 (2.42) 4.72 (1.08) 3.60 (1.50) 2.71 (1.52) 3.12 (1.90)
BGN LUM
CTL 5.51 (0.95) 4.47 (3.44) 2.65 (0.39) 5.79 (4.76) 1.38 (0.17) 0.66 (1.89) 2.08 (0.84) 3.28 (1.71)
GlcN 5.55 (0.97) 4.14 (3.49) 0.65 (0.45)*** 4.44 (4.58)*** 1.29 (0.14) 0.14 (1.63)*** 1.12 (0.83)*** 2.52 (1.63)***
NAPA 5.66 (0.95) 2.56 (3.36)*** 0.79 (0.42)*** 5.99 (5.12) 1.30 (0.12) 0.61 (1.64)*** 0.63 (0.57)*** 2.80 (1.48)**
G þ N 5.31 (1.13) 3.76 (3.53)*** 1.17 (0.46)*** 5.70 (4.68) 1.32 (0.11) 0.01 (1.71)*** 0.93 (0.73)*** 2.73 (1.71)***
DCN CD44
CTL 2.78 (0.43) 0.57 (0.44) 0.62 (0.97) 4.06 (2.69) 4.56 (0.49) 5.06 (3.82) 2.63 (1.69) 5.20 (1.75)
GlcN 2.83 (0.41) 0.72 (0.27) 0.27 (1.08) 3.34 (2.78)*** 4.78 (0.73) 4.51 (3.86)** 2.53 (1.72) 5.11 (1.65)
NAPA 2.68 (0.46) 0.66 (0.59) 0.16 (0.87)* 4.08 (2.69) 4.75 (0.63) 3.95 (3.78)*** 2.27 (1.85) 5.30 (1.23)
G þ N 2.71 (0.36) 0.84 (0.69) 0.40 (1.06) 3.59 (2.82)* 4.66 (0.81) 4.19 (3.94)*** 2.22 (1.84)* 5.44 (1.42)
SOX-9 HAS-2
CTL 4.09 (0.59) 4.97 (2.00) 4.72 (0.55) 5.94 (1.11) 7.96 (0.55) 7.84 (1.78) 7.58 (0.39) 8.57 (1.64)
GlcN 4.27 (0.49) 3.84 (2.00)*** 4.90 (0.27) 5.88 (1.06) 8.02 (0.51) 7.51 (1.84)* 7.38 (0.74) 8.93 (1.59)*
NAPA 4.00 (0.52) 2.56 (1.82)*** 4.29 (0.82)* 6.05 (1.13) 8.00 (0.54) 6.68 (1.89)*** 7.47 (0.73) 8.86 (1.49)
G þ N 4.07 (0.53) 3.49 (1.92)*** 3.61 (0.61)*** 6.21 (0.99) 7.92 (0.42) 7.59 (1.82) 6.19 (0.48)*** 8.84 (1.52)
IGF-I
CTL 10.14 (1.64) 10.56 (4.37) 7.50 (1.28) 10.57 (1.75)
GlcN 10.19 (1.65) 10.68 (4.20) 4.91 (1.34)*** 10.31 (1.59)
NAPA 10.11 (1.53) 10.57 (4.30) 5.13 (1.50)*** 9.66 (1.79)***
G þ N 9.94 (1.77) 10.82 (4.38) 6.25 (1.24)*** 10.41 (1.63)
*P < 0.05; **P < 0.01; ***P < 0.001.
D. Stoppoloni et al. / Osteoarthritis and Cartilage 23 (2015) 103e113 109laboratory9, on ECM synthesis in HPCs. NAPA was originally syn-
thesized, with other GlcN-derivatives9, in order to ﬁnd inhibitors of
Cathepsin B, which has been described to be involved in OA pa-
thology25. NAPA resulted the best Cathepsin inhibitor among the
new synthesized molecules. In the last years, GlcN has been used in
OA therapy with the aim to supply amino sugar for the synthesis of
GAG. Several trials have been conducted by orally administering
GlcN with inconsistent outcomes2e4. We decided to study the ef-
fects of GlcN and NAPA, which was more effective than GlcN in
inhibiting Cathepsin B, in a rabbit experimental OA, administering
the molecules by intra-articular injection. We found that both
molecules were able to induce a reconstitution of ECM, which had
been previously destroyed by intra-articular administration of
vitamin A. These effects were still evident 35 days after a single
injection of GlcN or NAPA10. These results prompted us to investi-
gate in vitro the molecular mechanisms underlying the effects of
the two molecules using chondrocytes, challenged with pro-
inﬂammatory cytokines, such as TNF-a and IL-1b15,16,26. We
thought that the inhibition of Cathepsin B alone was not enough to
explain the results described above. Indeed, we found that NAPA
and GlcN interfered with inﬂammatory and stress response
induced by cytokines, in particular they were able to interfere with
AP-1 pathway by inhibiting p38 and c-Jun N-terminal kinases
(JNK)15 and consequently by inhibiting Matrix MetalloProtease
(MMP)-1, -3 and -13 production. Next, we analyzed the ability of
GlcN and NAPA to inhibit NF-kB pathway, ﬁnding that both mole-
cules were able to inhibit IKKa nuclear translocation, but NAPAwas
also able to inhibit IKKa kinase activity16.
In the present study we were interested to understand whether
the reconstitution of ECM was a consequence of the anti-
inﬂammatory effect of GlcN and NAPA or whether there was a
direct effect of the twomolecules on the anabolic cell pathways.Weused HPCs obtained from areas of macroscopically normal cartilage
from total knee or hip arthroplasty.
In order to mimic chondrocyte physiological conditions we
cultured HPCs in tridimensional model by performing micromass
cultures.
In these culture conditions, we found that chondrocytes treated
with GlcN and mainly with NAPA or GlcN þ NAPA, after 2 weeks
exposure, showed a phenotype similar to healthy articular chon-
drocytes in vivo, consisting in abundant GAG deposition and Col2
production. Deposition of GAGwas almost comparable in GlcN- and
NAPA-treated samples and was more evident when the two mol-
ecules were administered at same time (G þ N). Col2 production
was enhanced by NAPA and by G þ N but was not stimulated by
GlcN at any concentration used (1, 2.5 and 5 mM). These ﬁndings
agree with the results reported by Uitterlinden et al.5,27. Interest-
ingly, micromasses treated with G þ N showed the highest GAG
deposition and highest production of Col2, which showed a cross-
banded morphology, suggesting that the two molecules have a
synergistic effect on ECM synthesis. Furthermore, we found that
NAPA and Gþ Nwere able to stimulate HA synthesis, whereas GlcN
was less effective.
Cartilaginous ECM is composed by several non-collagenous
components, such as SLRPs, such as Biglycan, Lumican and
Decorin28. We analyzed the ability of our molecules to stimulate
mRNA synthesis of BGN, LUM and DCN, ﬁnding that GlcN, NAPA and
G þ N were able to induce an increase in mRNA synthesis of BGN
and LUM and to a lesser extent of DCN. SLRPs are involved in a
variety of biological processes, including assembly of ECM, and
pathological processes, such as degenerative skeletal pro-
cesses29,30. For instance, SLRPs bind collagen ﬁbrils regulating their
kinetics, assembly and organization and at same time, protecting
them from cleavage by collagenase. Since Biglycan strongly
Fig. 5. Analysis of the copy number of mRNA of genes coding for ECM components compared to housekeeping gene, in untreated samples (CTL) cultured for 0, 4, 7 and 10 days.
Panel shows the results of the Q-RT-PCR used to quantify the mRNA levels of the following genes: Aggrecan (ACAN), Collagen2a1 (Col2), Collagen1a1 (Col1) and Collagen3a1 (Col3),
in untreated micromasses (CTL) at 0, 4, 7 and 10 days. Data are expressed as mRNA level calculated by 2DCt method and were analyzed by one-way ANOVA followed by Tukey's post
hoc test. Do signiﬁcant differences were observed in all cases. Data are reported as scatter plot and mean values obtained from each experiment.
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the early enhanced Col2 production by NAPA and GþN.We did not
ﬁnd an up-regulation of Aggrecan mRNA, but analyzing the
Aggrecan mRNA copy number normalized to housekeeping gene,
we found that this gene is present at high level in untreated sample
(CTL). The amount of Aggrecan mRNA, in micromass culture con-
dition, is higher compared with the amount present in cells culture
in monolayer, hence modulation are more difﬁcult to be appreci-
ated. Previously, we found that both GlcN and NAPA were able to
stimulate Aggrecan mRNA production in monolayer culture con-
ditions (unpublished data). On the other hand, Aggrecan gene
expression was previously shown to be unaffected by rediffer-
entiation of articular chondrocytes induced by culture on a
hyaluronan-based biomaterial31. The higher GAG content of
micromasses treated with our molecules could also be dependent
on the inhibiting activity of IKKa, and therefore of several ECM
degrading enzymes, including aggrecanase32.
Furthermore, we found enhanced production of hyaluronan and
increased mRNA expression of its tissue-speciﬁc transcription fac-
tor HAS-233, already at 4 days following NAPA treatment and at 7
days following G þ N treatment. The binding of aggrecan to hya-
luronan provides a mechanism for the ﬁxation of aggrecan within
the ECM. We found also an early enhanced expression of CD44, the
surface receptor, for hyaluronan and hence for aggrecan34. Finally
we found an up-regulation of Lumican, which has been demon-
strated to bind to aggrecan, contributing to the organization and
ﬁxation of aggrecan within ECM34. All these ﬁndings suggest that
treatment with GlcN and NAPA may contribute to improve the as-
sembly of ECM molecules providing a stabilization of chondrocyte
phenotype. The ECM synthesis in chondrocytes is under the control
of growth factors such as IGF-I, OP-1 and TGF-b18,35e38. Weanalyzed the IGF-I production, both at mRNA and protein level, and
found that our molecules up-regulate IGF-I. Loeser et al. reported
that OA chondrocytes show a decline in the response to IGF-I38. Our
ﬁndings are therefore interesting for the development of new
therapeutical strategies to treat OA, due to the ability of our mol-
ecules to rescue this IGF-I anabolic axis.
The concentrations of GlcN and NAPA used in the experiments
described in the present paper were 1 mM for GlcN and NAPA and
0.5 mMGlcNþ 0.5 mMNAPA. Although these concentrations, upon
oral administration, cannot be achieved in joints where GlcN rea-
ches approximately 10 mM39, we used them in order to gain insight
into the potential mechanisms of GlcN and its peptidyl-derivative
when injected intra-articularly. In our previous study, we re-
ported that GlcN and NAPAwere injected into rabbit joints at doses
as high as 2.5 mM concentration and this resulted in beneﬁcial
structure-modifying effects10. Thus, the concentrations used in this
study are within the range that can be reached after direct
administration into rabbit joints.
In conclusions, our study highlights that GlcN and NAPA show
the ability to stimulate the deposition of cartilage ECM, but with
some differences. NAPA stimulates HA and Col2 synthesis, whereas
GlcN was unable to stimulate Col2 and stimulates HA only at lower
extent. Other investigators have previously shown that GlcN
stimulated the synthesis of HA in aortic smooth muscle cells, by
supplying substrates for the synthesis of GAGs40. However, in our
experimental system, the GlcN-derivative NAPA proved to be more
effective than GlcN in GAGs stimulation. Therefore, we hypothesize
that the improved ECM deposition observed in GlcN treated
chondrocytes could be mainly due to the inhibition of MMP pro-
duction, as we previously described in Ref. 15 and to its ability to
inhibit the IKKa nuclear translocation16, whereas NAPA could be
Fig. 6. Effect of GlcN and NAPA on CD44, HA and IGF-I synthesis and on nuclear translocation of SOX-9 transcription factor. A, Harvested cell untreated (CTL) or treated with 1 mM
GlcN or with 1 mM NAPA or with 0.5 mM GlcN plus 0.5 mM NAPA (G þ N), were stained with CD44 (APC) antibody and 30,000 cells were assessed by ﬂow cytometry. The
percentage of CD44-positive cells is indicated in each quadrant. B, Results of immunohystochemical analysis of SOX-9 in parafﬁn-embedded micromasses untreated (CTL) or treated
with molecules, from one representative sample (original magniﬁcation 40). C, Measurement of HA levels quantitatively determined by ELISA. HA levels (ng) are reported as
scatter plot and mean values (horizontal bars) found in the medium (empty symbols) and in the cell lysate (ﬁlled symbols) of each of the three micromasses obtained by the three
donors. Each point of the scatter plot represents the average of duplicate observations made in the same sample. Two way ANOVA for repeated measures with treatment as the
between factor and type of sample (medium or cell lysate) as the within factor gave the following results: Ftreatment: 8.71, df: 3/8, P ¼ 0.0067; Fsample: 100.56, df: 1/8, P < 0.0001;
Finteraction: 0.85, df: 3/8, P ¼ 0.5045. **P < 0.01 and *P < 0.05 vs the respective type of sample of the CTL group (Bonferroni's post hoc test for multiple comparisons). D, Measurement
of IGF-I protein levels (pg) are reported as scatter plot and mean values (horizontal bars) found in the medium of each of the three micromasses obtained by the three donors. Each
point of the scatter plot represents the average of duplicate observations made in the same sample. The one-way ANOVA gave the following results: F: 102.6, df: 3/11, **P < 0.01 vs
CTL (Dunnett's post hoc test for multiple comparisons).
D. Stoppoloni et al. / Osteoarthritis and Cartilage 23 (2015) 103e113 111more involved in the synthesis of new ECM components. Previ-
ously, we found that NAPA selectively inhibits IKKa kinase activity16
and nowwe show that this molecule stimulates synthesis of Col2 as
well as proteoglycan production. A connection between IKKa and
Col2 synthesis has been studied by Olivotto et al.32,41 who found
that IKKa knock out cells show an increase in Col2 production,
which derives from both transcriptional and post-translational
mechanisms. The synergistic effects observed by treating cells
with G þ N could be due to the cumulative effects of the two
molecules on different pathways and on both anabolism and
catabolism. This is relevant since OA treatment ideally should take
advantage of molecules that have not only the ability to neutralize
the destructive capacity of inﬂammatory mediators, but also the
ability to stimulate the intrinsic capacity of chondrocytes to syn-
thesize new cartilage components.Author contributions
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